The U.S FDA approved a new treatment for type 2 diabetes. This treatment for type 2 diabetes is a Tradjenta (linagliptin) tablets. This treatment is to be down with a diet and exercise plan, which improves the blood sugar control in person who has type 2 diabetes. Those who have type 2 diabetes, normally have no insulin production response, it is a hormone which regulates the level of sugar in the blood.
If this hormone becomes unresponsive than patient suffers with serious complications, which includes blindness, heart disease nerve damage and kidney damage. Type 2 diabetes is the most common disease which is affecting around 8 percent of the United States population. Tradjenta tablets enhance the response of insulin producing hormone that releases the insulin after a person have meal by jamming the dipeptidyl peptidase-4 or DPP-4 enzyme.
“This approval provides another treatment option for the millions of Americans with Type 2 diabetes. It is effective when used alone or when added to existing treatment regimens.” ,” said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research.
Tradjenta was appeared as an effective and safe within placebo-controlled clinical research which is done on 3,800 type 2 diabetes patients. This research showed control in blood sugar. Tradjenta is researched as single therapy and in combination with other therapies of Type 2 diabetes which includes pioglitazone, metformin and glimepiride. It has not been researched with the combination of insulin and should not be used to treat persons who have increased Ketones in their urine or blood which is know as diabetic ketoacidosis. It also be not used with the persons who have Type 1 diabetes.
As far as side effects are concerned, it may have most common side effects which includes stuffy or runny nose, muscle pain, sore throat, headache and are upper respiratory infection. These tables will be dispensed with FDA-approved patient pack which has the explanation of the use of this drug and also its risk factors. Tradjenta is in market by Indianapolis-based Eli Lilly Co. and Boehringer Ingelheim Pharmaceuticals Inc.